Advertisement
Screener

SUTRO BIOPHARMA, INC. (STRO) Auditor

SUTRO BIOPHARMA, INC. Auditor

The independent registered public accounting firm that signed the audit report in each annual report on Form 10-K, newest first. PCAOB firm ID and the internal-control attestation are as tagged on the cover from fiscal 2021; earlier rows come from the signed report text.

  • 2026-03-23: Fiscal year end 2025-12-31; Auditor Ernst & Young LLP; PCAOB firm ID 42; Location San Mateo, California.
  • 2025-03-13: Fiscal year end 2024-12-31; Auditor Ernst & Young LLP; PCAOB firm ID 42; Location San Mateo, California.
  • 2024-03-25: Fiscal year end 2023-12-31; Auditor Ernst & Young LLP; PCAOB firm ID 42; Location San Mateo, California.
  • 2023-03-30: Fiscal year end 2022-12-31; Auditor Ernst & Young LLP; PCAOB firm ID 42; Location San Mateo, California.
FiledFiscal year endAuditorPCAOB firm IDLocationInternal-control attestation
2026-03-232025-12-31Ernst & Young LLP42San Mateo, CaliforniaNo
2025-03-132024-12-31Ernst & Young LLP42San Mateo, CaliforniaYes
2024-03-252023-12-31Ernst & Young LLP42San Mateo, CaliforniaNo
2023-03-302022-12-31Ernst & Young LLP42San Mateo, California
2022-02-282021-12-31Ernst & Young LLP42Redwood City, CaliforniaYes
2021-03-182020-12-31Ernst & Young LLPRedwood City, CaliforniaNo
2020-03-162019-12-31Ernst & Young LLPRedwood City, California
2019-04-012018-12-31Ernst & Young LLPRedwood City, California

Similar stocks

Stock NameCountryMarket CapPE Ratio
Invivyd, Inc. (IVVD)United States$0.270B-2.42
PALISADE BIO, INC. (PALI)United States$0.275B-11.41
Lexeo Therapeutics, Inc. (LXEO)United States$0.278B-4.19
Lineage Cell Therapeutics, Inc. (LCTX)United States$0.241B-10.35
FATE THERAPEUTICS INC (FATE)United States$0.280B-2.51
Liminatus Pharma, Inc. (LIMN)United States$0.282B
Aligos Therapeutics, Inc. (ALGS)United States$0.238B-0.47
Inhibikase Therapeutics, Inc. (IKT)United States$0.296B-4.44
X4 Pharmaceuticals, Inc (XFOR)United States$0.297B-4.99
Protalix BioTherapeutics, Inc. (PLX)$0.221B9.87